Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2018

01-07-2018 | Research Article

Preoperative plasma fibrinogen is associated with poor prognosis in esophageal carcinoma: a meta-analysis

Authors: G. Y. Lv, Y. Yu, L. An, X. D. Sun, D. W. Sun

Published in: Clinical and Translational Oncology | Issue 7/2018

Login to get access

Abstract

Purpose

The aim of this meta-analysis was to investigate preoperative plasma fibrinogen (PPF) as a prognostic marker in esophageal carcinoma (EC) by meta-analysis.

Methods

Relevant studies were sought in the databases including Pubmed, Web of Science, Cochrane library, and Wanfang databases up to Oct 10th, 2017. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used as effective value, and pooled HRs were synthesized by STATA 14.0 to assess the prognostic impact of PPF on EC patients.

Results

A total of 8 studies with 2827 patients were collected in this meta-analysis. Our results revealed that high PPF was significantly associated with poor OS (HR = 1.90, 95% CI 1.56–2.33, P = 0.000; HR = 1.76, 95% CI 1.28–2.42, P = 0.000) and poor DFS (HR = 1.91, 95% CI 1.50–2.43, P = 0.000; HR = 1.51, 95% CI 1.16–1.97, P = 0.000) in EC patients from univariate and multivariate analysis results, respectively, which suggested that EC patients with high PPF will suffer from high postoperative mortality and recurrence rate.

Conclusion

High PPF was significantly associated with poor OS and DFS in EC patients. Fibrinogen can serve as a prognostic marker and even a future targeting molecule during the treatment of EC patients.
Literature
1.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27.CrossRefPubMedCentral
2.
3.
4.
Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res. 2001;102(6):V187–94.CrossRefPubMed
5.
Kołodziejczyk J, Ponczek MB. The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemp Oncol (Pozn). 2013;17(2):113–9.PubMedPubMedCentral
6.
Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79–83.CrossRefPubMed
7.
Ebrahimi S, Rahmani F, Behnam-Rassouli R, Hoseinkhani F, Parizadeh MR, Keramati MR, et al. Proinflammatory signaling functions of thrombin in cancer. J Cell Physiol. 2017;232(9):2323–9.CrossRefPubMed
8.
Blombäck B, Blombäck M. The molecular structure of fibrinogen. Ann NY Acad Sci. 1972;8(202):77–97.CrossRef
9.
Pulanić D, Rudan I. The past decade: fibrinogen. Coll Antropol. 2005;29(1):341–9.PubMed
10.
Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43–62.CrossRefPubMed
11.
Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49–60.CrossRefPubMed
12.
Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann NY Acad Sci. 2001;936:406–25.CrossRefPubMed
13.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMed
14.
Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans. 2002;30(2):201–7.CrossRefPubMed
15.
Perisanidis C, Psyrri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960–70.CrossRefPubMed
16.
Ilhan-Mutlu A, Starlinger P, Perkmann T, Schoppmann SF, Preusser M, Birner P. Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. Biomark Med. 2015;9(4):327–35.CrossRefPubMed
17.
18.
Matsuda S, Takeuchi H, Fukuda K, Nakamura R, Takahashi T, Wada N, et al. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus. 2014;27(7):654–61.CrossRefPubMed
19.
20.
Stang A. Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
21.
Sun XD, Shi XJ, Chen YG, Wang CL, Ma Q, Lv GY. Elevated preoperative neutrophil–lymphocyte ratio is associated with poor prognosis in hepatocellular carcinoma patients treated with liver transplantation: a meta-analysis. Gastroenterol Res Pract. 2016;2016:4743808. https://​doi.​org/​10.​1155/​2016/​4743808 (Epub 2015 Dec 30).PubMedCrossRef
22.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
23.
24.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed
25.
26.
Wakatsuki K, Matsumoto S, Migita K, Ito M, Kunishige T, Nakade H, et al. Preoperative plasma fibrinogen is associated with lymph node metastasis and predicts prognosis in resectable esophageal cancer. World J Surg. 2017;41(8):2068–77.CrossRefPubMed
27.
Zhang SS, Lei YY, Cai XL, Yang H, Xia X, Luo KJ, et al. Preoperative serum fibrinogen is an independent prognostic factor in operable esophageal cancer. Oncotarget. 2016;7(18):25461–9.PubMedPubMedCentral
28.
Qiao CR, Zhao S, Li XN, Zhao J, Zhu DY, Wu K, et al. The prognostic and clinicopahtological role of peripheral plasma fibrinogen and platelete in esophageal squamous cell carcinoma. Chin J of Gerontol. 2016;1(36):348–50 (Article in Chinese).
29.
Zhang D, Zhou X, Bao W, Chen Y, Cheng L, Qiu G, et al. Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma. Oncotarget. 2015;6(35):38410–20.PubMedPubMedCentral
30.
Arigami T, Okumura H, Matsumoto M, Uchikado Y, Uenosono Y, Kita Y, et al. Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma: a promising blood marker of tumor progression and prognosis. Medicine (Baltimore). 2015;94(42):e1702.CrossRefPubMedPubMedCentral
31.
Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22(12):2222–7.CrossRefPubMed
32.
Kijima T, Arigami T, Uchikado Y, Uenosono Y, Kita Y, Owaki T, et al. Combined fibrinogen and neutrophil–lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. Cancer Sci. 2017;108(2):193–9.CrossRefPubMedPubMedCentral
33.
Suzuki T, Shimada H, Nanami T, Oshima Y, Yajima S, Washizawa N, et al. Prognostic significance of hyperfibrinogenemia in patients with esophageal squamous cell carcinoma. Int J Clin Oncol. 2017;22(3):461–8.CrossRefPubMed
34.
Tan Z, Zhang M, Han Q, Wen J, Luo K, Lin P, et al. A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the fibrinogen/albumin ratio. J Cancer. 2017;8(6):1025–9.CrossRefPubMedPubMedCentral
35.
Li XH, Wang XP, Gu WS, Lin JH, Huang H, Kang T, et al. Clinical significance of preoperative thrombin time in patients with esophageal squamous cell carcinoma following surgical resection. PLoS ONE. 2015;10(10):e0140323.CrossRefPubMedPubMedCentral
36.
Wayman J, O’Hanlon D, Hayes N, Shaw I, Griffin SM. Fibrinogen levels correlate with stage of disease in patients with oesophageal cancer. Br J Surg. 1997;84(2):185–8.CrossRefPubMed
37.
Zhao C, Su Y, Zhang J, Feng Q, Qu L, Wang L, et al. Fibrinogen-derived fibrinostatin inhibits tumor growth through anti-angiogenesis. Cancer Sci. 2015;106(11):1596–606.CrossRefPubMedPubMedCentral
38.
Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302–9.PubMed
Metadata
Title
Preoperative plasma fibrinogen is associated with poor prognosis in esophageal carcinoma: a meta-analysis
Authors
G. Y. Lv
Y. Yu
L. An
X. D. Sun
D. W. Sun
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1794-z

Other articles of this Issue 7/2018

Clinical and Translational Oncology 7/2018 Go to the issue

Review Article

Clinical implications of the deregulated TP73 isoforms expression in cancer

Research Article

Curative radiation therapy for very elderly bladder cancer patients with localized disease

Research Article

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer

Research Article

Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients

Correction

Correction to: Curative radiation therapy for very elderly bladder cancer patients with localized disease

Review Article

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits